CN108096307A - Application of the eupatorium lindleynun var. trifoliolatum ethanol extract in anti-hepatic-B virus medicine is prepared - Google Patents
Application of the eupatorium lindleynun var. trifoliolatum ethanol extract in anti-hepatic-B virus medicine is prepared Download PDFInfo
- Publication number
- CN108096307A CN108096307A CN201810045561.1A CN201810045561A CN108096307A CN 108096307 A CN108096307 A CN 108096307A CN 201810045561 A CN201810045561 A CN 201810045561A CN 108096307 A CN108096307 A CN 108096307A
- Authority
- CN
- China
- Prior art keywords
- eupatorium
- hepatitis
- ethanol extract
- trifoliolatum
- lindley
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000735527 Eupatorium Species 0.000 title claims abstract description 73
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 239000000469 ethanolic extract Substances 0.000 title claims abstract description 20
- 241000700605 Viruses Species 0.000 title abstract description 6
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- 241001478387 Eupatorium lindleyanum Species 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 13
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 5
- 244000025254 Cannabis sativa Species 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 101710142246 External core antigen Proteins 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 238000002474 experimental method Methods 0.000 abstract description 7
- 101710132601 Capsid protein Proteins 0.000 abstract description 6
- 239000000427 antigen Substances 0.000 abstract description 6
- 102000036639 antigens Human genes 0.000 abstract description 6
- 108091007433 antigens Proteins 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 229960001627 lamivudine Drugs 0.000 abstract description 6
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract description 6
- 208000006454 hepatitis Diseases 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 25
- -1 diterpenoid compound Chemical class 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000284 extract Substances 0.000 description 15
- 150000004354 sesquiterpene derivatives Chemical group 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical group O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 241000700721 Hepatitis B virus Species 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 229930004069 diterpene Natural products 0.000 description 8
- 229910001175 oxide dispersion-strengthened alloy Inorganic materials 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 244000062748 Eupatorium adenophorum Species 0.000 description 7
- YFZSQPRYLBGYKE-UHFFFAOYSA-N Jaceoside Natural products C1=C(O)C(OC)=CC(C=2OC3=CC(OC4C(C(O)C(O)C(CO)O4)O)=C(OC)C(O)=C3C(=O)C=2)=C1 YFZSQPRYLBGYKE-UHFFFAOYSA-N 0.000 description 7
- 229930003944 flavone Natural products 0.000 description 7
- 235000011949 flavones Nutrition 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- GLAAQZFBFGEBPS-UHFFFAOYSA-N jaceosidin Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O)=C(OC)C(O)=C3C(=O)C=2)=C1 GLAAQZFBFGEBPS-UHFFFAOYSA-N 0.000 description 7
- AOAPCDXPLWGVGI-UHFFFAOYSA-N jaceosidin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccc(O)c(C)c3 AOAPCDXPLWGVGI-UHFFFAOYSA-N 0.000 description 7
- XRHHDQSPFPQKMS-UHFFFAOYSA-N sudachitin Natural products C1=C(O)C(OC)=CC(C=2OC3=C(OC)C(O)=C(OC)C(O)=C3C(=O)C=2)=C1 XRHHDQSPFPQKMS-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 150000002212 flavone derivatives Chemical class 0.000 description 6
- 150000002596 lactones Chemical class 0.000 description 6
- 229930004725 sesquiterpene Natural products 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- APOGLVUGPAVNAP-UHFFFAOYSA-N (9-hydroxy-6,10-dimethyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl) 4-hydroxy-2-methylbut-2-enoate Chemical compound OCC=C(C)C(=O)OC1CC(C)=CCC(O)C(C)=CC2OC(=O)C(=C)C12 APOGLVUGPAVNAP-UHFFFAOYSA-N 0.000 description 5
- HPWMABTYJYZFLK-UHFFFAOYSA-N [9-acetyloxy-6-(acetyloxymethyl)-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] 4-hydroxy-2-methylbut-2-enoate Chemical compound OCC=C(C)C(=O)OC1CC(COC(=O)C)=CCC(OC(C)=O)C(C)=CC2OC(=O)C(=C)C21 HPWMABTYJYZFLK-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- INXZZSZBRLXKNT-NMLBUPMWSA-N eupalinolide F Natural products CC(=O)O[C@H]1CC=C(/CO)C[C@@H](OC(=O)C(=CCO)C)[C@@H]2[C@H](OC(=O)C2=C)C=C/1C INXZZSZBRLXKNT-NMLBUPMWSA-N 0.000 description 5
- HPWMABTYJYZFLK-CBPXPLCBSA-N eupalinolide G Natural products CC(=O)OCC1=CC[C@H](OC(C)=O)C(C)=C[C@H]2OC(=O)C(=C)[C@@H]2[C@@H](C1)OC(=O)C(C)=CCO HPWMABTYJYZFLK-CBPXPLCBSA-N 0.000 description 5
- INXZZSZBRLXKNT-WTGUMLROSA-N eupalinolide H Natural products CC(=O)O[C@@H]1CC=C(/CO)C[C@@H](OC(=O)C(=CCO)C)[C@@H]2[C@H](OC(=O)C2=C)C=C/1C INXZZSZBRLXKNT-WTGUMLROSA-N 0.000 description 5
- HPWMABTYJYZFLK-YSFYHYPLSA-N eupalinolide I Natural products CC(=O)OCC1=C/C[C@@H](OC(=O)C)C(=C/[C@H]2OC(=O)C(=C)[C@@H]2[C@@H](C1)OC(=O)C(=CCO)C)C HPWMABTYJYZFLK-YSFYHYPLSA-N 0.000 description 5
- APOGLVUGPAVNAP-BRSBDYLESA-N eupalinolide K Natural products CC(=C/CO)C(=O)O[C@@H]1CC(=CC[C@@H](O)C(=C[C@H]2OC(=O)C(=C)[C@H]12)C)C APOGLVUGPAVNAP-BRSBDYLESA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 5
- 229960005375 lutein Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 5
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 5
- 235000008210 xanthophylls Nutrition 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920002647 polyamide Polymers 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- MTVPOQKYYUETRT-UHFFFAOYSA-N Eupatilin Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 MTVPOQKYYUETRT-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 244000018795 Prunus mume Species 0.000 description 2
- 235000011158 Prunus mume Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000000311 effect on hepatitis Effects 0.000 description 2
- FHHSEFRSDKWJKJ-UHFFFAOYSA-N eupafolin Natural products C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=C(O)C(O)=C1 FHHSEFRSDKWJKJ-UHFFFAOYSA-N 0.000 description 2
- DRRWBCNQOKKKOL-UHFFFAOYSA-N eupatilin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(O)C=C2O1 DRRWBCNQOKKKOL-UHFFFAOYSA-N 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 description 1
- 206010059193 Acute hepatitis B Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- QKHWMRCPHBKIKP-UHFFFAOYSA-N COc(cc(c1c2OC)OC(c(cc3[O](C)=C)ccc3[O](C)=C)=CC1=O)c2[O](C)=C Chemical compound COc(cc(c1c2OC)OC(c(cc3[O](C)=C)ccc3[O](C)=C)=CC1=O)c2[O](C)=C QKHWMRCPHBKIKP-UHFFFAOYSA-N 0.000 description 1
- 240000000230 Chromolaena odorata Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000011229 Prunus domestica subsp. syriaca Nutrition 0.000 description 1
- 244000169641 Spondias dulcis Species 0.000 description 1
- 235000005138 Spondias dulcis Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 241000062949 Tremula Species 0.000 description 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000122 inhibitory effect on hepatitis Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960005311 telbivudine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of application of eupatorium lindleynun var. trifoliolatum ethanol extract in anti-hepatic-B virus medicine is prepared.Eupatorium lindleynun var. trifoliolatum ethanol extract is prepared in the present invention from eupatorium lindleynun var. trifoliolatum, this its progress anti-hepatitis virus HBV experiment, the result shows that it is respectively provided with the effect for significantly inhibiting hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg, there is better pharmaceutical activity compared with treating the clinical medicine lamivudine (3TC) of hepatitis B.Eupatorium lindleynun var. trifoliolatum ethanol extract of the present invention can be used for the drug for preparing anti-hepatitis virus.
Description
Technical Field
The invention relates to an application of an ethanol extract of lindley eupatorium in preparing anti-hepatitis B virus medicines.
Background
Hepatitis B Virus (HBV) infection is one of main diseases affecting human health, about 3 hundred million people are chronic hepatitis B virus carriers worldwide, China is the country with the most hepatitis B virus carriers, about 0.93 hundred million people, acute hepatitis B is easy to be converted into chronic hepatitis, even deteriorates into cirrhosis and liver cancer, at present, domestic medicines for treating chronic viral hepatitis are mainly 1, orally taken nucleoside (acid) chemical medicines, such as lamivudine, adefovir, entecavir, telbivudine, tenofovir and the like, but easily generate drug resistance, 2, biological preparations, interferons, such as interferon α and pegylated interferon α, which are commonly used, but most patients have rebound phenomenon after drug withdrawal, and the interferon is expensive (about 2-4 yuan for each course of treatment), cannot be taken through gastrointestinal tract, is inconvenient to use, easily generates side effects after long-term administration, such as side effects of similar symptoms and traditional platelet reduction and the like, 3, traditional Chinese medicines, ziguo acid and derivatives thereof, polysaccharides, and plant chemical polysaccharides, and medicaments for improving liver diseases, especially the immune response of Japanese apricot yellow plum virus, the liver disease, the drug development of Japanese apricot kernel, the drug development, the drug metabolism, the liver disease, the research of China, the research of the medicine, the research of traditional Chinese medicine, the research of the.
Herba Eupatorii Lindleyanum DC of Compositae is herba Eupatorii Lindleyanum, and is prepared from herba Eupatorii Lindleyanum DC. Has bitter taste and mild nature, enters liver and spleen meridians, has the functions of eliminating phlegm and stopping cough, clearing heat and releasing toxin, inducing diuresis and reducing edema and reducing blood pressure, and is used for treating cold, cough and excessive phlegm, headache, tonsillitis, bacillary dysentery and hypertension (see: the national traditional Chinese medicine administration, Chinese materia medica, Shanghai: Shanghai science and technology publisher, 1999:7,6876). The extract of lindley eupatorium has the effect of protecting rats with acute lung injury, the compound lindley eupatorium capsule has a certain inhibiting effect on influenza viruses in vitro, the concentrated solution of lindley eupatorium syrup has a certain antibacterial effect on gram positive and negative bacteria and candida albicans, and the extract of lindley eupatorium total flavonoids has the effect of reducing blood viscosity (see: Jianzhou, Yanghui, Hoohai Xixia, etc. the extract of lindley eupatorium has a certain inhibiting effect on gram positive and gram negative bacteria and candida albicans. the research on the protective effect of lindley eupatorium on acute lung injury of rats, Chinese pharmacy 2007, 18 (27): 4; Zhou Dazhou, Wu Yan Jian, etc. the experiment research on the anti-influenza viruses of compound lindley eupatorium, Chinese patent medicine, 2008, 30 (5): 650-650, Wan Kejing, Qin Jiang, Cheng Zhun, etc. the research on the pharmacological and clinical effects of Chinese medicine, 2009, 25(2): 80-82. ) However, whether the lindley eupatorium has the effect of resisting the hepatitis B virus is not reported, and the invention finds that the lindley eupatorium has the activity of resisting the hepatitis B virus.
Disclosure of Invention
The invention aims to: provides an application of an ethanol extract of lindley eupatorium in preparing anti-hepatitis B virus medicaments.
The technical scheme of the invention is as follows: the application of lindley eupatorium herb in preparing the anti-hepatitis B virus medicine is that the lindley eupatorium herb is an ethanol extract of the lindley eupatorium herb, and the ethanol extract is obtained by adopting the following method: taking dry eupatorium lindleyanum whole grass, cutting the eupatorium lindleyanum into sections of 2-3 cm, adding 8-15 times of ethanol aqueous solution with volume fraction of 60-95%, refluxing and extracting for 1-3 hours, repeating for 1-3 times, and recovering the solvent under reduced pressure at 40-60 ℃ to obtain the eupatorium lindleyanum ethanol extract.
The lindley eupatorium herb is a lindley eupatorium herb flavone part containing jaceosidin and eupatorium xanthophyll, and the chemical structural formulas of the lindley eupatorium herb are respectively as follows:
the lindley eupatorium is a lindley eupatorium sesquiterpene part containing lindley eupatorium lactone F, lindley eupatorium lactone G, lindley eupatorium lactone H, lindley eupatorium lactone I and lindley eupatorium lactone K; the chemical structural formula is as follows:
the lindley eupatorium herb is an eluted part of lindley eupatorium herb with 70% ethanol water, and is prepared by the following method: taking dry eupatorium lindleyanum whole grass, cutting the eupatorium lindleyanum into sections of 2-3 cm, adding 8-15 times of ethanol aqueous solution with volume fraction of 60-95%, refluxing and extracting for 1-3 hours, repeating for 1-3 times, and recovering the solvent under reduced pressure at 40-60 ℃ to obtain an eupatorium lindleyanum ethanol extract; dissolving the extract in water to prepare a solution with the concentration of 0.5-1 g/ml, adsorbing the solution by weak-polarity macroporous adsorption resin, eluting by water to remove macromolecular compounds, eluting by 90-95% ethanol aqueous solution by volume fraction, and recovering the solvent at 40-60 ℃ under reduced pressure to obtain a macroporous resin part; adsorbing the obtained macroporous resin part by an ODS (oxide dispersion strengthened) reverse phase silica gel chromatographic column, eluting by 50% methanol aqueous solution by volume fraction, then eluting by 70% -75% methanol aqueous solution, recovering the solvent at 40-60 ℃ under reduced pressure, adsorbing by a 30-60 mesh polyamide chromatographic column, and eluting by 70% ethanol aqueous solution by volume fraction to obtain the lindley eupatorium 70% ethanol aqueous part.
Further, preferably, the weak polar macroporous absorption resin is AB-8, D101, HPD-100, HPD-200A, HPD-200B, HPD-300, HPD-700 or HPD-722 macroporous absorption resin;
further, preferably, the ODS reversed-phase silicA gel chromatographic column is A DAISOGEL ODS reversed-phase silicA gel filler with the particle size of 50-70 um, A Cosmsil ODS reversed-phase silicA gel filler with the particle size of 50-70 um or A YMCODS-A reversed-phase silicA gel filler with the particle size of 50-70 um;
furthermore, preferably, the volume ratio of the water to the low-polarity macroporous adsorption resin is 8-15: 1; the volume ratio of the 90-95% ethanol aqueous solution to the macroporous adsorption resin is 8-15: 1; the mass ratio of the volume of the ODS reversed phase silica gel chromatographic column to the obtained macroporous resin part is 20-30: 1; the volume ratio of the 50% methanol aqueous solution to the 70-75% methanol aqueous solution to the ODS reversed phase silica gel chromatographic column is 5-8: 1; the mass ratio of the volume of the polyamide chromatographic column to the adsorbed sample is 20-30: 1; the volume ratio of the 70% ethanol aqueous solution to the polyamide chromatographic column is 4-10: 1.
The lindley eupatorium is a lindley eupatorium medium-chain diterpenoid compound selected from (1)3- (hydroxymethy) -1, 14, 15-trihydroxy-7, 11, 15-trimethy-2, 6, 10-hexadecainen-13-acetate and (2)3- (hydroxymethy) -1, 13, 15-trihydroxy-7, 11, 15-trimethy-2, 6, 10-hexadecainen-14-acetate, and the structural formulas of the compounds are respectively as follows:
the four extracts and two chain diterpenoid compounds are subjected to in vitro anti-hepatitis B virus HBV experiments to obtain the extract which has obvious inhibition effect on hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg, and the extract has obvious anti-hepatitis B virus HBV effect and can be used for preparing anti-hepatitis B virus medicines.
The invention has the advantage of providing a new source for anti-hepatitis B virus medicines.
Drawings
The invention is further described with reference to the following figures and examples:
FIG. 1 is a high performance liquid chromatogram of a tremula sesquiterpene locus of example 2;
FIG. 2 is a high performance liquid chromatogram of control Eupalinolide F in example 2;
FIG. 3 is a high performance liquid chromatogram of control Eupalinolide G of example 2;
FIG. 4 is the HPLC chromatogram of control substance Eupalinolide H in example 2;
FIG. 5 is a high performance liquid chromatogram of control Eupalinolide I in example 2;
FIG. 6 is a high performance liquid chromatogram of control Eupalinolide K in example 2;
FIG. 7 is a high performance liquid chromatogram of the lindley eupatorium herb flavone site in example 2;
FIG. 8 is the HPLC chromatogram of the control Eupatorium adenophorum xanthophyll in example 2;
FIG. 9 is a high performance liquid chromatogram of a control jaceosidin from example 2;
Detailed Description
The invention is further illustrated by the following examples.
Example 1: preparation method of herba Eupatorii Lindleyani extract and herba Eupatorii Lindleyani medium chain diterpene compound
(1) Weighing 1000g of eupatorium lindleyanum dry whole grass, cutting into sections of 2-3 cm, adding 15 times volume of 80% ethanol aqueous solution, carrying out reflux extraction for 2 hours, repeating the extraction for 2 times, recovering the solvent at 60 ℃ under reduced pressure to obtain 158g of eupatorium lindleyanum ethanol extract (EUP-EtOH), dissolving the EUP-EtOH) in about 150ml of water, adsorbing the eupatorium lindleyanum ethanol extract (EUP-EtOH) by 1800ml of AB-8 macroporous adsorption resin, eluting by 20000ml of water to remove macromolecular compounds, eluting by 20000ml of 95% ethanol aqueous solution at 60 ℃ under reduced pressure to recover the solvent to obtain 61g of macroporous resin parts; adsorbing the obtained macroporous resin part with 1500ml Cosmsil ODS reversed phase silica gel column with particle size of 70um, eluting with 10000ml methanol water solution with volume fraction of 50%, and recovering solvent under reduced pressure at 60 deg.C to obtain 21g of Eupatorium eupatorium sesquiterpene part (EUP-SQT). Then 10000ml of 70% methanol aqueous solution is used for elution, the solvent is recycled under reduced pressure at 60 ℃ to obtain 20g of extract, the extract is absorbed by 600ml of 30-60 mesh polyamide chromatographic column, 4000ml of 70% ethanol aqueous solution is used for elution, and the solvent is recycled under reduced pressure at 60 ℃ to obtain 14.7g of lindley eupatorium 70% ethanol aqueous elution part (EUP-DIT). Eluting with 4000ml 100% ethanol, and recovering solvent at 60 deg.C under reduced pressure to obtain 2.8g of herba Eupatorii Lindleyani flavone fraction (EUP-FLA).
(2) Preparation of lindley eupatorium chain diterpene compound: drying herba Eupatorii Lindleyani 2000g, extracting with 10 times of 80% ethanol-water under reflux for 2 times, each for 2 hr, mixing filtrates, and recovering ethanol under reduced pressure to obtain 250g extract; dissolving the extract in 100mL of water, extracting with 100mL of petroleum ether for degreasing, extracting with chloroform twice (100 mL each time), and concentrating the chloroform extraction layer at 30 deg.C under reduced pressure to obtain about 11g of chloroform; the chloroform fraction was subjected to 300g of silica gel column chromatography and eluted with chloroform-methanol 100:2 to give 1.08g of an eluted fraction. Performing column chromatography with 200mL Rohm and Haas resin column, eluting with 60% -80% methanol-water system, collecting 0.5g of 80% methanol eluate, performing silicA gel column chromatography, eluting with chloroform-methanol (50:1) to obtain 112mg of 2A, preparing 2A with high performance liquid chromatography, preparing chromatograph with Beijing Huideyi ILC-P3050, chromatographic column YMC-PackODS-A column (250mm £ 20mm, YMC, Kyoto, Japan), detecting wavelength of 210nm, eluting with 70% methanol-water system, separating at flow rate of 5mL/min for 38.5min to obtain 31mg of compound (A), and separating at 42.8min to obtain 26mg of compound (b).
Example 2: detection of sesquiterpene fraction, flavone fraction and active ingredient of mid-chain diterpene compound
(1) Detecting active ingredients of Eupatorium eupatorium sesquiterpene part (EUP-SQT): in this example, the components were determined by HPLC. High performance liquid chromatography (Agilent 1260Infinity, Agilent, usa) wherein mobile phase a is acetonitrile; the mobile phase B is water; the mobile phase conditions are shown in table 1. A chromatographic column: YMC-PACK ODS-A (phi 4.6 mm. times.250 mm,5 μm); column temperature: 28 ℃; detection wavelength: 210 nm; sample introduction amount: 20 mu l of the mixture; flow rate: 1 ml. min-1。
TABLE 1 HPLC chromatographic analysis conditions
Time (min) | Mobile phase A (%) | Mobile phase B (%) |
0 | 30 | 70 |
5 | 30 | 70 |
15 | 32 | 68 |
25 | 36 | 64 |
40 | 36 | 64 |
6.02mg of reference substances, namely eupalinolide F, 14.94mg of eupalinolide G, 5.08mg of eupalinolide H, 10.04mg of eupalinolide I and 13.98mg of eupalinolide K are precisely weighed respectively, and the volume is fixed to 10ml by using a mobile phase A to serve as a stock solution. Adding mobile phase A, diluting to 1:2, 1:4, 1:8, 1:16 and 1:32, filtering with 0.22 μm filter membrane, and filtering to obtain filtrate. 5 concentrations of control were chromatographed and a standard curve was plotted, with 3 replicates per concentration point. Recording peak areas of the chromatographic peaks, and performing linear regression on the concentration (x) of the chromatographic peaks by using peak areas (y) of a reference substance to obtain a standard curve of the reference substance, wherein eupalinolide F, y is 63403 x-15.408; eupalinolide G, y 24720 x-20.065; eupalinolide H, y 79063x + 6.7811; eupalinolide I, y 239018x + 53.303; eupalinolide K, y 7913.5x + 62.857.
The EUP-SQT 6mg of eupatorium sesquiterpene prepared in example 1 was precisely weighed, the volume was determined to 10ml by mobile phase a volumetric flask, and the filtrate was filtered through a 0.22 μm membrane filter and subjected to chromatography.
FIGS. 1-6 are HPLC chromatograms of sesquiterpene positions (EUP-SQT) from Eupatorium, control products eupalinolide F, eupalinolide G, eupalinolide H, eupalinolide I and eupalinolide K.
By analyzing the high performance liquid chromatography result, eupatorium pseudochinensis (EUP-SQT) part samples containing eupatorium pseudochinensis F (eupatorium pseudochinensis F), eupatorium pseudochinensis G (eupatorium pseudochinensis G), eupatorium pseudochinensis H (eupatorium pseudochinensis H), eupatorium pseudochinensis I (eupatorium pseudochinensis I) and eupatorium pseudochinensis K (eupatorium pseudochinensis K) can be obtained, the chromatographic signal values of the samples are substituted into a standard curve, and the specific content of each component is further obtained, and the specific content is shown in Table 2.
TABLE 2 Eupatorium lappacans sesquiterpene fraction (EUP-SQT) sample containing 5 Eupatorium lappacans lactone
Sample (I) | eupalinolide F | eupalinolide G | eupalinolide H | eupalinolide I | eupalinolide K | Ratio of |
Content (wt.) | 4.1% | 31.8% | 6.8% | 3.4% | 47.7% | 93.8% |
(2) Detecting active ingredients of eupatorium lindleyanum flavone part (EUP-FLA): the method is similar to the detection of active ingredients of Eupatorium eupatorium sesquiterpene part. The conditions of the high performance liquid chromatography are as follows: mobile phase a was acetonitrile (containing 0.1% formic acid); mobile phase B was water (containing 0.1% formic acid); mobile phase conditions: see table 3; a chromatographic column: YMC-PACKODS-A (Φ 4.6 mm. times.250 mm,5 μm); column temperature: 28 ℃; detection wavelength: 365 nm; sample introduction amount: 20 mu l of the mixture; flow rate: 1 ml. min-1。
TABLE 3 HPLC chromatogram analysis conditions
Time (min) | Mobile phase A (%) | Mobile phase B (%) |
0 | 36 | 64 |
15 | 36 | 64 |
30 | 90 | 10 |
Precisely weighing control substances of eupatorium lucolium xanthophyll 4.67mg and jaceosidin 8.17mg respectively; and adding mobile phase A to a constant volume of 10ml to obtain stock solution, diluting with mobile phase A to obtain 1:2, 1:4, 1:8, 1:16 and 1:32, and filtering with 0.22 μm filter membrane to obtain filtrate. 5 concentrations of control were chromatographed and a standard curve was plotted, with 3 replicates per concentration point. Recording the peak area of each chromatographic peak, and performing linear regression on the concentration (x) by using the peak area (y) of a reference substance to obtain a standard curve of the reference substance, wherein eupatilin y is 52964x +19.30, and jaceosidin y is 55161x + 210.79.
6mg of the EUP-FLA sample of the eupatorium lindley EUP prepared in example 1 is precisely weighed, the volume is determined to 10ml by using the mobile phase A, the solution is filtered by a 0.22 mu m filter membrane, and the filtrate is respectively taken for chromatographic determination.
FIGS. 7-9 are high performance liquid chromatograms of a sample of Eupatorium odoratum flavone, a control of eupatilin, and a control of jaceosidin.
Analyzing by high performance liquid chromatography to obtain eupatorium adenophorum xanthophyll and jaceosidin in the sample of eupatorium adenophorum flavone part, and substituting the chromatographic signal value of the sample into a standard curve to further obtain the specific content of each component, as shown in Table 4.
TABLE 4 content of 2 flavones in Eupatorium lindleyanum flavone part
Sample (I) | Eupatorium xanthophyll | Jaceosidin | Total ratio of |
Content (wt.) | 26.0% | 66.1% | 92.1% |
(3) Detection of active ingredients of eupatorium lindleyanum medium-chain diterpenoid compounds: the compound (a) and the compound (b) prepared in example 1 were measured for spectrum, and the spectrum data were as follows:
the compound (a) is colorless oil, and the infrared spectrum IR (KBr) shows vmax:3424,2974,2930,1717,1653,1373,1258,1024cm-1(ii) a HR-ESI-MS gives the molecular ion peak M/z 421.2568[ M + N [ ]a]+(calcd forC22H38O6Na, 421.2561), indicating that its molecular formula is C22H38O6. It is composed of1H NMR and13c NMR spectra in CDCl3The measurement in (1). The results are shown in Table 1;
the compound (b) is colorless oil, and the infrared spectrum IR (KBr) shows vmax:3402,2972,2932,1653,1576,1418,1051,1015cm-1(ii) a HR-ESI-MS gives the molecular ion peak M/z 421.2565[ M + Na ]]+(calcd.forC22H38O6Na, 421.2561), indicating that its molecular formula is C22H38O6. It is composed of1H NMR and13c NMR spectra in CDCl3The measurement in (1). The results are shown in Table 5 below,
TABLE 5 preparation of the compounds (a), (b)1H NMR and13c NMR spectrum data
Wherein,1h NMR and13c NMR was performed at 400MHz and 125MHz, respectively.
By infrared spectrum, HR-ESI-MS and,1H NMR and13data analysis of C NMR spectra, in comparison with literature (see: Shuangqing Wu, Naiyu Xu, Jian Zhang, Shi Yao, Chunjun Chu. three new antibacterial reagents from Eupatorium linleyanum DC.. Journal of Asian Natural product research.2012,14(7):652-656.), consistent spectroscopic data, indicates: compound (a) is compound (1): 3- (hydroxymethy) -1, 14, 15-trihydroxy-7, 11, 15-trimethyl-2, 6, 10-hexadecacarrien-13-acetat, and the structural formula of the compound is as follows:
compound (b) is compound (2): 3- (hydroxymethy) -1, 13, 15-trihydroxy-7, 11, 15-trimethyl-2, 6, 10-hexadecacarrien-14-acetate, the structural formula of the compound is as follows:
example 3: external anti-HBV experiment of four eupatorium lindleyanum extracts and eupatorium lindleyanum medium-chain diterpene compounds
1. Experimental drugs and reagents: the chain diterpene compounds (1) and (2) were prepared in the above example 1; dimethyl sulfoxide; MTT (thiazole blue), shanghai jianlai biotechnology limited; control drug, lamivudine tablet (3 TC); kurarin Schk pharmaceuticals (Suzhou) Inc.; a cell culture medium DMEM, a growth medium and a preparation, wherein the growth medium contains 10% fetal calf serum, 380 mug/ml G418, 0.03% glutamine, penicillin, streptomycin and the like, and each 100 mug/ml;
2. experimental equipment: ELISA kit for detecting hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg; an incubator; 24-well plates, and the like.
3. Cell lines: 2.2.15 cell line of Hep G2, department of education/Ministry of health, molecular virology focus laboratory, Shanghai.
4. The experimental method comprises the following steps:
a2.2.15 cell line of Hep G2 was collected at 10X 10 cells per well5Individual cells were seeded in 24-well plates at 5% CO2Culturing at 37 ℃ in an incubator, after 48 hours, respectively replacing the growth liquid with drug culture liquids containing the compound (1) and the compound (2) which are dissolved by dimethyl sulfoxide, setting 5 concentrations of each group of drug culture liquids to be 12.5 mu g/ml-200 mu g/ml (as shown in table 2), setting 4 parallel holes for each concentration, continuing culturing for 9 days, and replacing the liquid once every 3 days. Positive control groupThe drug is lamivudine (3TC), the culture solution without drug is used as a blank control group, 1 hole is respectively arranged on each of the two control groups, and the operation of the two control groups is the same as that of the drug culture solution except that the growth solution is correspondingly changed into the lamivudine drug and the culture solution without drug. Collecting supernatant, detecting the content of HBsAg and HBeAg by using an ELISA kit, and simultaneously determining the toxicity of the two groups of compounds on cells by using MTT (methyl thiazolyl tetrazolium) at different concentrations. The results are shown in Table 6.
The above experimental procedures were repeated with ethanol extract of Eupatorium Adianum, Eupatorium Adianum flavone fraction, Eupatorium Adianum sesquiterpene fraction, and Eupatorium Adenanum 70% ethanol eluted fraction, respectively, to obtain the results shown in Table 6.
As can be seen from Table 6, both the chain diterpene compounds (1) and (2) had inhibitory effects on hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg. The compounds (1) and (2) inhibit HBsAg and HBeAg, and the inhibition rate increases with the increase of concentration; when the compound (1) is at 50 mu g/mL, the inhibition rate of the compound on HBsAg and HBeAg is obviously higher than 3 TC; under the same concentration of the compound (2) and the 3TC, the inhibition rate of the compound (2) on HBsAg and HBeAg is obviously higher than that of the 3 TC; the compounds (1) and (2) at low concentrations had a high inhibitory rate against HBsAg and HBeAg as compared with 3 TC.
The ethanol extract, flavone part, sesquiterpene part, and 70% ethanol-eluted part of Eupatorium Adianum have effects of inhibiting HBsAg and HBeAg, and increasing the inhibition rate with increasing concentration; compared with 3TC, the low-concentration Eupatorium Adenophorum hand Mazz extract, Eupatorium Adenophorum hand Mazz fraction, and Eupatorium Adenophorum hand Mazz fraction with 70% ethanol elution fraction all have high inhibitory effect on hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg.
TABLE 6 anti-HBV test results of four groups of Eupatorium Adenophorum extracts and two groups of chain diterpene compounds
Wherein, the ratio of +: "show toxicity" means a cell viability of < 75%; /: no inhibition rate test was performed.
The above examples can obtain that the drug prepared by extracting the lindley eupatorium ethanol extract, the lindley eupatorium flavone part, the lindley eupatorium sesquiterpene part, the lindley eupatorium 70% ethanol water elution part and the two chain diterpenoid compounds from the lindley eupatorium shows obvious inhibition effect on hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg in an in vitro anti-hepatitis B virus HBV experiment, and has better drug activity compared with the clinical drug lamivudine (3TC) for treating hepatitis B. Therefore, the ethanol extract, the flavonoid part, the sesquiterpene part, the 70% ethanol water elution part and two chain diterpene compounds extracted from the lindley eupatorium herb can be used for preparing the anti-hepatitis B virus medicines.
Claims (1)
1. An application of an ethanol extract of lindley eupatorium in preparing anti-hepatitis B virus medicines is characterized in that the ethanol extract is obtained by adopting the following method: taking dry eupatorium lindleyanum whole grass, cutting the eupatorium lindleyanum into sections of 2-3 cm, adding 8-15 times of ethanol aqueous solution with volume fraction of 60-95%, refluxing and extracting for 1-3 hours, repeating for 1-3 times, and recovering the solvent under reduced pressure at 40-60 ℃ to obtain the eupatorium lindleyanum ethanol extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810045561.1A CN108096307B (en) | 2014-06-04 | 2014-06-04 | Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810045561.1A CN108096307B (en) | 2014-06-04 | 2014-06-04 | Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine |
CN201410244607.4A CN104069145B (en) | 2014-06-04 | 2014-06-04 | Application of the eupatorium lindleynun var. trifoliolatum in anti-hepatic-B virus medicine is prepared |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410244607.4A Division CN104069145B (en) | 2014-06-04 | 2014-06-04 | Application of the eupatorium lindleynun var. trifoliolatum in anti-hepatic-B virus medicine is prepared |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108096307A true CN108096307A (en) | 2018-06-01 |
CN108096307B CN108096307B (en) | 2021-02-05 |
Family
ID=51591011
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810045561.1A Active CN108096307B (en) | 2014-06-04 | 2014-06-04 | Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine |
CN201810045547.1A Active CN108245501B (en) | 2014-06-04 | 2014-06-04 | Application of chained diterpene compound of lindley eupatorium in preparing anti-hepatitis B virus medicine |
CN201810045554.1A Active CN108159099B (en) | 2014-06-04 | 2014-06-04 | Application of eupatorium sesquiterpene part in preparation of anti-hepatitis B virus medicine |
CN201410244607.4A Active CN104069145B (en) | 2014-06-04 | 2014-06-04 | Application of the eupatorium lindleynun var. trifoliolatum in anti-hepatic-B virus medicine is prepared |
CN201810046069.6A Active CN108113985B (en) | 2014-06-04 | 2014-06-04 | Application of eupatorium lindleyanum flavone part in preparation of anti-hepatitis B virus medicines |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810045547.1A Active CN108245501B (en) | 2014-06-04 | 2014-06-04 | Application of chained diterpene compound of lindley eupatorium in preparing anti-hepatitis B virus medicine |
CN201810045554.1A Active CN108159099B (en) | 2014-06-04 | 2014-06-04 | Application of eupatorium sesquiterpene part in preparation of anti-hepatitis B virus medicine |
CN201410244607.4A Active CN104069145B (en) | 2014-06-04 | 2014-06-04 | Application of the eupatorium lindleynun var. trifoliolatum in anti-hepatic-B virus medicine is prepared |
CN201810046069.6A Active CN108113985B (en) | 2014-06-04 | 2014-06-04 | Application of eupatorium lindleyanum flavone part in preparation of anti-hepatitis B virus medicines |
Country Status (1)
Country | Link |
---|---|
CN (5) | CN108096307B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108096307B (en) * | 2014-06-04 | 2021-02-05 | 苏州大学 | Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine |
CN105288513A (en) * | 2015-12-07 | 2016-02-03 | 包永昌 | Traditional Chinese medicine composition for treating hepatitis B and cirrhosis |
CN106309529B (en) * | 2016-10-25 | 2019-11-12 | 南京中医药大学 | A kind of preparation method of eupatorium lindleynun var. trifoliolatum active component |
CN116354912B (en) * | 2021-12-27 | 2023-11-14 | 杭州亦坚生物医药科技有限公司 | Compound and application thereof in serving as or preparing ABCG2 agonist |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001003681A2 (en) * | 1999-07-08 | 2001-01-18 | Prendergast Patrick T | Use of flavones, coumarins and related compounds to treat infections |
CN1486699A (en) * | 2003-09-04 | 2004-04-07 | 江苏省中医药研究院 | Application of the effective part of Chinese medicinal material lindley eupatorium herb in preparing antiviral medicine |
CN1785174A (en) * | 2005-11-09 | 2006-06-14 | 中国药科大学 | Application of wogonin for preparing medicine to treat or prevent hepatitis B |
CN103340916A (en) * | 2013-07-18 | 2013-10-09 | 重庆市中药研究院 | Lindley eupatorium extract as well as preparation method and application thereof |
CN103520153A (en) * | 2013-10-22 | 2014-01-22 | 苏州大学 | Application of Eupalinolide K in preparing anticomplement drugs |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02138289A (en) * | 1988-08-29 | 1990-05-28 | Nippon Mektron Ltd | Novel diterpenoid glycoside preventive and improver for hypertension comprising same glycoside as medicinal component and production thereof |
DE19644422C2 (en) * | 1996-10-25 | 2000-06-15 | Stefan Schulz | Use of terpenes to treat autoimmune diseases and graft rejection |
CN100515230C (en) * | 2006-01-12 | 2009-07-22 | 重庆佳易医疗器械有限公司 | New medicinal use of eupatorium lindleyanun |
JP2013071901A (en) * | 2011-09-27 | 2013-04-22 | Saishunkan Seiyakusho:Kk | Cosmetic for inhibiting melanin production |
CN102389456A (en) * | 2011-11-29 | 2012-03-28 | 苏州大学 | Method for extracting isodon japonica var.galaucocalyx total diterpenoids or Glaucocalyxin A |
CN103142628A (en) * | 2013-02-05 | 2013-06-12 | 广西壮族自治区药用植物园 | Application of diterpenoid compound in treating hepatitis c virus (HCV) |
CN103191386B (en) * | 2013-03-22 | 2014-04-30 | 刘晓燕 | Medicament for treating chronic hepatitis B |
CN103655544B (en) * | 2013-12-02 | 2016-03-30 | 滨州医学院 | The application of Jaceosidin in preparation prevention or the Fibrotic medicine for the treatment of chronic hepatic injury regulating liver-QI |
CN108096307B (en) * | 2014-06-04 | 2021-02-05 | 苏州大学 | Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine |
CN107243005A (en) * | 2017-05-04 | 2017-10-13 | 浙江中医药大学 | A kind of anti-cancer composition extracted from eupatorium lindleynun var. trifoliolatum and its preparation method and application |
-
2014
- 2014-06-04 CN CN201810045561.1A patent/CN108096307B/en active Active
- 2014-06-04 CN CN201810045547.1A patent/CN108245501B/en active Active
- 2014-06-04 CN CN201810045554.1A patent/CN108159099B/en active Active
- 2014-06-04 CN CN201410244607.4A patent/CN104069145B/en active Active
- 2014-06-04 CN CN201810046069.6A patent/CN108113985B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001003681A2 (en) * | 1999-07-08 | 2001-01-18 | Prendergast Patrick T | Use of flavones, coumarins and related compounds to treat infections |
CN1486699A (en) * | 2003-09-04 | 2004-04-07 | 江苏省中医药研究院 | Application of the effective part of Chinese medicinal material lindley eupatorium herb in preparing antiviral medicine |
CN1785174A (en) * | 2005-11-09 | 2006-06-14 | 中国药科大学 | Application of wogonin for preparing medicine to treat or prevent hepatitis B |
CN103340916A (en) * | 2013-07-18 | 2013-10-09 | 重庆市中药研究院 | Lindley eupatorium extract as well as preparation method and application thereof |
CN103520153A (en) * | 2013-10-22 | 2014-01-22 | 苏州大学 | Application of Eupalinolide K in preparing anticomplement drugs |
Non-Patent Citations (1)
Title |
---|
吴双庆,等: "野马追化学成分", 《中国中药杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN104069145B (en) | 2018-04-27 |
CN108159099A (en) | 2018-06-15 |
CN108159099B (en) | 2021-03-26 |
CN108113985B (en) | 2020-07-21 |
CN108096307B (en) | 2021-02-05 |
CN108245501B (en) | 2020-07-24 |
CN108245501A (en) | 2018-07-06 |
CN108113985A (en) | 2018-06-05 |
CN104069145A (en) | 2014-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101062071B (en) | Total saponins from radix bupleuri extract and the preparing method thereof | |
CN104257715B (en) | Herba Artemisiae extract and its preparation method and application | |
CN100998621B (en) | Radix sileris total chromone extractive and its preparation method | |
CN101073595A (en) | Glycyrrhiza total flavonoid and total saponin extract and its production | |
CN101863871B (en) | Total glycosides of Rhodiola rosea, medical application and preparation method thereof | |
CN101062078A (en) | Extract of stevia whole stevioside and stevia whole flavone and the preparing method thereof | |
CN101062069A (en) | Whole coumarins extract from root of dahuriae angelica and the preparing method thereof | |
CN104069150B (en) | Preparation method of honeysuckle extract | |
CN104069145B (en) | Application of the eupatorium lindleynun var. trifoliolatum in anti-hepatic-B virus medicine is prepared | |
CN102286056A (en) | Oleanolic acid derivative and preparation method thereof | |
CN103819445A (en) | Method for preparing two neo-pentenyl flavonoid compounds with hypolipidemic activity in fructus podophylli | |
CN104370871B (en) | The mouth diphenylene ketone oxide class separated from Swertia punicea Hemsl. and the application of suppression hepatitis B virus | |
CN101856435B (en) | Preparation method and content determination method of Daphne giraldii Nitsche total coumarin extract | |
CN102688261A (en) | Pteris multifida extract, preparation method thereof and use thereof | |
CN109232491A (en) | The Preparation method and use of benzofuran compounds in a kind of Herba Serissae | |
CN104027403B (en) | A kind of preparation method of Radix Polygalae sugar ester effective site | |
CN107129478B (en) | Semi-terpene lactone compound and preparation method and application thereof | |
CN104398950A (en) | Four-flavored calamus anticancer extract, as well as preparation method and application of four-flavored calamus anticancer extract | |
CN102670698B (en) | The application of Radix Flemingiae Philippinensis extract in preparation control diabetes medicament | |
CN101816702B (en) | Lung cancer preventing and treating composition extracted from selfheal and/or garden orache and application thereof in preparation of lung cancer preventing and treating medicine | |
CN104983789A (en) | Separating method for fine active dracocephalum heterophyllum component and application of fine active dracocephalum heterophyllum component | |
CN108096302A (en) | A kind of Herba Rostellulariae extract of platelet aggregation-against and its preparation method and application | |
CN104586925B (en) | Redback christmashush root extract and preparation method and preparation treatment hepatitis B medicine application | |
TWI685345B (en) | Artemisia extracts for inhibiting lung cancer cells | |
CN102526154B (en) | Method for preparing antitumor medicine burdock root extractive |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |